search
Back to results

Amniotic Membrane Therapy for Interstitial Cystitis/Painful Bladder Syndrome

Primary Purpose

Interstitial Cystitis, Painful Bladder Syndrome, Painful Bladder Syndrome (PBS)

Status
Not yet recruiting
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Clarix Flo
Placebo
Sponsored by
David Sheyn
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Interstitial Cystitis focused on measuring interstitial cystitis, painful bladder syndrome

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria: Patients 18 years of age or older Female English Speaking Diagnosis of IC/PBS Have failed at least one prior treatment for IC/PBS Exclusion Criteria: Patients less than 18 years of age Unable to provide consent Non-English speaking Patients with known anatomical malformations of the ureters, bladder, or urethra

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Amniotic Membrane Therapy

    Placebo

    Arm Description

    Under general anesthesia, cystoscopy will be performed. A needle will be inserted into the detrusor muscle to a depth of approximately 2 mm. 100mg of commercially available micronized amniotic membrane (Clarix Flo; BioTissue, Miami, FL) diluted in 10 mL of 0.9% preservative-free sodium chloride, and 0.5 mL of the solution will be injected into 20 equally spaced sites into the posterior and lateral walls of the bladder, sparing the dome and the trigone.

    Under general anesthesia, cystoscopy will be performed. A needle will be inserted into the detrusor muscle to a depth of approximately 2 mm. 0.5 mL of 10 mL of 0.9% preservative-free sodium chloride will be injected into 20 equally spaced sites into the posterior and lateral walls of the bladder, sparing the dome and the trigone.

    Outcomes

    Primary Outcome Measures

    Change in Interstitial Cystitis Symptom Index (ICSI) score
    Evaluate for clinically-meaningful reduction in symptoms as defined as a 5 point reduction in Interstitial Cystitis Symptom Index (ICSI)

    Secondary Outcome Measures

    Change in Interstitial Cystitis Symptom Index Questionnaire
    To determine the change in interstitial cystitis symptoms in participants who received amniotic membrane injection versus placebo injection (saline) as measured using the Interstitial Cystitis Symptom Index (ICSI).
    Change in Interstitial Cystitis Problem Index Questionnaire
    To determine the change in interstitial cystitis symptoms in participants who received amniotic membrane injection versus placebo injection (saline) as measured using the Interstitial Cystitis Problem Index (ICPI).
    Change in Bladder Pain/ Interstitial Cystitis Symptom Score
    To determine the change in interstitial cystitis symptoms in participants who received amniotic membrane injection versus placebo injection (saline) as measured using the Bladder Pain/Interstitial Cystitis Symptom Score (BPIC-SS).
    Change in Overactive Bladder Assessment Tool Scores
    To determine the change in interstitial cystitis symptoms in participants who received amniotic membrane injection versus placebo injection (saline) as measured using the Overactive Bladder Assessment Tool
    Change in SF-12 Health Survey Scores
    To determine the change in interstitial cystitis symptoms in participants who received amniotic membrane injection versus placebo injection (saline) as measured using the SF-12 Health Survey
    Change in number of urinary tract infections as measured by medical record review
    As defined by symptoms of urinary tract infection and positive urine culture

    Full Information

    First Posted
    October 17, 2023
    Last Updated
    October 17, 2023
    Sponsor
    David Sheyn
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT06096597
    Brief Title
    Amniotic Membrane Therapy for Interstitial Cystitis/Painful Bladder Syndrome
    Official Title
    Amniotic Membrane Therapy for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS): a Prospective, Double-Blind, Randomized Controlled Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    January 2024 (Anticipated)
    Primary Completion Date
    January 2026 (Anticipated)
    Study Completion Date
    January 2026 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    David Sheyn

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Interstitial cystitis/painful bladder syndrome (IC/PBS) is a clinical syndrome in which patients report symptoms of bladder and/or pelvic pain with pressure and/ or discomfort associated with urinary frequency and urgency. The primary objective of this study is to determine the efficacy of amniotic membrane therapy in patients with interstitial cystitis/painful bladder syndrome (IC/PBS) as defined by clinically-significant improvement in validated symptom questionnaires.
    Detailed Description
    Interstitial cystitis/painful bladder syndrome (IC/PBS) is a clinical syndrome in which patients report symptoms of bladder and/or pelvic pain with pressure and/or discomfort associated with urinary frequency and urgency. These symptoms vary in severity and are known to cause significant impact on quality of life. Current recommended therapies include behavior modifications, stress management practices, physical therapy, oral pharmacologic pain management agents, intravesical instillations, hydrodistension, fulguration of bladder lesions and/or triamcinolone injections, intradetrusor onabotulinumtoxin A injections, neuromodulation, and major surgery. Amniotic membranes, Clarix FLO™, have been used to assist in wound healing in many fields of medicine, and its use has evolved over the last century to various applications in regenerative medicine. A novel study using amniotic membranes for bladder therapy has showing promising preliminary results in a small cohort study of 10 females with recalcitrant IC/PBS. These women underwent intradetrusor injections of micronized amniotic membranes and had significant improvement of voiding symptoms and bladder pain over 3 months with no adverse events. No randomized controlled trials (RCT) of amniotic bladder therapy have been conducted to date. The proposed study would be the first RCT assessing the efficacy of amniotic membrane injections with Clarix FLO™ and has the potential to make significant impacts in the management and treatment of patients with IC/PBS. Clarix FLO™ is a sterile, particulate human amniotic membrane and umbilical cord tissue product that is aseptically processed in compliance with current Good Tissue Practices from the same donated human tissue (placenta) after determination of eligibility and placenta/cord suitability. Amniotic Membrane and Umbilical Cord products are currently designated by the FDA as tissue products under PHS Act 361 HCT/P (human cells, tissues and cellular and tissue-based products). Clarix FLO™ does not contain living cells. Patients will then be followed with clinical evaluation and questionnaires repeated at 2, 4, 8 and 12 weeks post-operatively. Additional urine culture and post void residuals will be repeated at 2 and 4 weeks post-operatively. Primary Objective: Determine the efficacy of amniotic bladder therapy (ABT) in patients with interstitial cystitis/painful bladder syndrome (IC/PBS) as defined by clinically-significant improvement - Clinically-meaningful indicator defined as: 5 point reduction in Interstitial Cystitis Symptom Index (ICSI) Secondary Objectives: Characterize duration of effect of ABT using clinical evaluation and the following questionnaires: Interstitial Cystitis Symptom Index (ICSI) Interstitial Cystitis Problem Index (ICPI) Bladder Pain/Interstitial Cystitis Symptom Score (BPIC-SS) Overactive Bladder Assessment Tool SF-12 Health Survey - Page 2 of 5 [DRAFT] - Determine if there are any adverse effects of ABT, such as urinary tract infections or acute urinary retention. Hypothesis: ABT in patients with PBS improves clinical outcomes

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Interstitial Cystitis, Painful Bladder Syndrome, Painful Bladder Syndrome (PBS)
    Keywords
    interstitial cystitis, painful bladder syndrome

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Single Group Assignment
    Masking
    ParticipantCare ProviderInvestigator
    Masking Description
    At time of surgery, the surgeon will be given a sealed envelope containing a sterile syringe of either 10 mL of 0.9% preservative-free sodium chloride or 100 mg of commercially available micronized AM (Clarix Flo; BioTissue, Miami, FL) diluted in 10 mL of 0.9% preservative-free sodium chloride
    Allocation
    Randomized
    Enrollment
    100 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Amniotic Membrane Therapy
    Arm Type
    Experimental
    Arm Description
    Under general anesthesia, cystoscopy will be performed. A needle will be inserted into the detrusor muscle to a depth of approximately 2 mm. 100mg of commercially available micronized amniotic membrane (Clarix Flo; BioTissue, Miami, FL) diluted in 10 mL of 0.9% preservative-free sodium chloride, and 0.5 mL of the solution will be injected into 20 equally spaced sites into the posterior and lateral walls of the bladder, sparing the dome and the trigone.
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    Under general anesthesia, cystoscopy will be performed. A needle will be inserted into the detrusor muscle to a depth of approximately 2 mm. 0.5 mL of 10 mL of 0.9% preservative-free sodium chloride will be injected into 20 equally spaced sites into the posterior and lateral walls of the bladder, sparing the dome and the trigone.
    Intervention Type
    Drug
    Intervention Name(s)
    Clarix Flo
    Intervention Description
    100 mg of commercially available micronized amniotic membrane (Clarix Flo; BioTissue, Miami, FL) diluted in 10 mL of 0.9% preservative-free sodium chloride
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Intervention Description
    10 mL of 0.9% preservative-free sodium chloride
    Primary Outcome Measure Information:
    Title
    Change in Interstitial Cystitis Symptom Index (ICSI) score
    Description
    Evaluate for clinically-meaningful reduction in symptoms as defined as a 5 point reduction in Interstitial Cystitis Symptom Index (ICSI)
    Time Frame
    To be completed pre-operatively and at 2, 4, 8 and 12 weeks post-operatively
    Secondary Outcome Measure Information:
    Title
    Change in Interstitial Cystitis Symptom Index Questionnaire
    Description
    To determine the change in interstitial cystitis symptoms in participants who received amniotic membrane injection versus placebo injection (saline) as measured using the Interstitial Cystitis Symptom Index (ICSI).
    Time Frame
    To be completed pre-operatively and at 2, 4, 8 and 12 weeks post-operatively
    Title
    Change in Interstitial Cystitis Problem Index Questionnaire
    Description
    To determine the change in interstitial cystitis symptoms in participants who received amniotic membrane injection versus placebo injection (saline) as measured using the Interstitial Cystitis Problem Index (ICPI).
    Time Frame
    To be completed pre-operatively and at 2, 4, 8 and 12 weeks post-operatively
    Title
    Change in Bladder Pain/ Interstitial Cystitis Symptom Score
    Description
    To determine the change in interstitial cystitis symptoms in participants who received amniotic membrane injection versus placebo injection (saline) as measured using the Bladder Pain/Interstitial Cystitis Symptom Score (BPIC-SS).
    Time Frame
    To be completed pre-operatively and at 2, 4, 8 and 12 weeks post-operatively
    Title
    Change in Overactive Bladder Assessment Tool Scores
    Description
    To determine the change in interstitial cystitis symptoms in participants who received amniotic membrane injection versus placebo injection (saline) as measured using the Overactive Bladder Assessment Tool
    Time Frame
    To be completed pre-operatively and at 2, 4, 8 and 12 weeks post-operatively
    Title
    Change in SF-12 Health Survey Scores
    Description
    To determine the change in interstitial cystitis symptoms in participants who received amniotic membrane injection versus placebo injection (saline) as measured using the SF-12 Health Survey
    Time Frame
    To be completed pre-operatively and at 2, 4, 8 and 12 weeks post-operatively
    Title
    Change in number of urinary tract infections as measured by medical record review
    Description
    As defined by symptoms of urinary tract infection and positive urine culture
    Time Frame
    To be completed pre-operatively and at 2, 4, 8 and 12 weeks post-operatively

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Patients 18 years of age or older Female English Speaking Diagnosis of IC/PBS Have failed at least one prior treatment for IC/PBS Exclusion Criteria: Patients less than 18 years of age Unable to provide consent Non-English speaking Patients with known anatomical malformations of the ureters, bladder, or urethra
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Margot Le Neveu, MD
    Phone
    2013063828
    Email
    Margot.LeNeveu@uhhospitals.org
    First Name & Middle Initial & Last Name or Official Title & Degree
    David Sheyn, MD
    Phone
    5132252314
    Email
    David.Sheyn@uhhospitals.org
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    David Sheyn, MD
    Organizational Affiliation
    University Hospitals Cleveland Medical Center
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Amniotic Membrane Therapy for Interstitial Cystitis/Painful Bladder Syndrome

    We'll reach out to this number within 24 hrs